Althea Well Positioned to Reach 4,000 Patients in Australia by December 2019

  • Oct 25, 2019 AEDT
  • Team Kalkine

Althea Group Holdings Limited (ASX: AGH), an Australian medical cannabis company, provided a market update of its operations.

  • 2,705 patients have now been prescribed Althea medicinal cannabis products in Australia;
  • 348 Healthcare Professionals have prescribed Althea medicinal cannabis products in Australia;
  • In the UK, the Company received further Home Office import licences for supply of Althea’s medicinal cannabis products;
  • Aphria and Althea’s commercial relationship continues with a variation of the current product supply agreement which provides continuity of product supply up to the year 2027.

At AEST 1:03PM, the stock was trading at $0.435 per share, down by 17.14% from its previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK